We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Method Enables Detection of Lung Cancer through Blood Tests

By LabMedica International staff writers
Posted on 02 Feb 2024
Print article
Image: Using blood tests to diagnose lung cancer can be less invasive for patients (Photo courtesy of 123RF)
Image: Using blood tests to diagnose lung cancer can be less invasive for patients (Photo courtesy of 123RF)

Lung cancer continues to be a very deadly disease with only 19% of diagnosed patients remaining alive after five years. This makes it important to accurately detect the different forms of lung cancer, each with its own treatment and approach, at an early stage so that patients can be better treated. Currently, there is a gold standard for determining whether someone has lung cancer. If suspected, the first step is a scan, such as CT or PET CT. That gives insight into where the symptoms may be coming from and the location of possible cancer cells or a tumor. The second step is a biopsy in which a ‘morsel’ of tissue is removed and examined under the microscope. However, evidence of tumor cells cannot always be obtained. Additionally, sometimes people are too old or too sick and the biopsy itself is too risky for their health. Also, sometimes people refuse to undergo the procedure. Now, researchers have developed a method to demonstrate the presence of lung cancer through blood tests by examining proteins in the blood of people with, without, and with possible lung cancer. This method can be developed in the future, to make it suitable for predicting lung cancer.

To find a testing method that is much less invasive for lung cancer patients, researchers at Eindhoven University of Technology (TU/e, Netherlands) first examined blood from three groups of people: with, without, and with possible lung cancer to ascertain the proteins. Interestingly, they found that in 13% of patients, the current gold standard could not conclusively determine whether or not these patients had lung cancer. The patient survey provided a huge database the researchers were able to work with. The team developed new detection methods for quantifying two promising lung cancer protein tumor markers based on liquid chromatography-tandem mass spectrometry (LC-MS/MS). This is a method that looks at the weight of proteins in the blood and thus recognizes tumor markers.

This allowed the researchers to detect these markers even at very low concentrations in the blood of patients with lung cancer. The new methods can help in follow-up studies to find out whether LC-MS/MS-based detection can also add value in clinical practice in the hospital compared to current methods. To facilitate the step to the hospital or clinical practice, the team has developed not only the diagnostic method but also a decision algorithm for GPs. Since GPs have to pay attention to a combination of factors instead of just one marker, the decision algorithm can help them correctly interpret blood test results according to the new method. The researchers are now preparing to conduct a study to validate the method which could one day allow people to go to their doctor and get a blood test to find out whether they have lung cancer.

“Blood sampling is much less painful and risky. Especially for the high-risk lung cancer group, where smoking and age are the main risk factors,” said Sylvia Roovers-Genet, a PhD researcher at TU/e. “We have now scientifically proven that lung cancer can be demonstrated in blood. We can now use our method, based on blood tests, to be able to say with at least 95 percent certainty for two-thirds of patients that they have lung cancer.”

Related Links:
TU/e

Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Thyroid Stimulating Hormone Assay
Neonatal TSH ELISA Kit
New
EBV DNA Quantitative Fluorescence Diagnostic Kit
S3015E EBV

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The discovery of a new blood group has solved a 50- year-old mystery (Photo courtesy of 123RF)

Newly Discovered Blood Group System to Help Identify and Treat Rare Patients

The AnWj blood group antigen, a surface marker discovered in 1972, has remained a mystery regarding its genetic origin—until now. The most common cause of being AnWj-negative is linked to hematological... Read more

Microbiology

view channel
Image: The Accelerate Arc System has been granted US FDA 510(k) clearance (Photo courtesy of Accelerate Diagnostics)

Automated Positive Blood Culture Sample Preparation Platform Designed to Fight Against Sepsis and AMR

Delayed administration of antibiotics to patients with bloodstream infections significantly increases the risk of morbidity and mortality. For optimal therapeutic outcomes, it is crucial to rapidly identify... Read more

Pathology

view channel
Image: Confocal- & laminar flow-based detection scheme of intact virus particles, one at a time (Photo courtesy of Paz Drori)

Breakthrough Virus Detection Technology Combines Confocal Fluorescence Microscopy with Microfluidic Laminar Flow

Current virus detection often relies on polymerase chain reaction (PCR), which, while highly accurate, can be slow, labor-intensive, and requires specialized lab equipment. Antigen-based tests provide... Read more

Industry

view channel
Image: Last year, Seegene and Werfen has entered into a collaboration on the OneSystem business to develop syndromic qPCR assays (Photo courtesy of Seegene)

Seegene and Werfen Finalize Partnership Agreement on Technology-Sharing Initiative

Seegene (Seoul, South Korea), a leading PCR molecular diagnostics company, and Werfen (Barcelona, Spain), a global diagnostics specialist, have finalized a partnership agreement as part of a technology-sharing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.